← All Eikon Therapeutics, INC filings

Eikon Therapeutics, INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

NASDAQ
EIKN
Eikon Therapeutics, INC
8-K: Eikon Therapeutics Reports Q2 2026 Results, Clinical Progress
Eikon Therapeutics announced second quarter 2026 financial results, highlighting clinical advancements in its oncology portfolio and a robust cash reserve.
NASDAQ
EIKN
Eikon Therapeutics, INC
8-K: Eikon Therapeutics Board Sees Two Director Departures
Eikon Therapeutics announced the resignations of two board members, Leon Chen and Joshua Wolfe, effective July 31, 2026.
NASDAQ
EIKN
Eikon Therapeutics, INC
8-K: Eikon Therapeutics Updates on Promising Clinical Trial Data
Eikon Therapeutics presented updated clinical trial data for its EIK1001 and EIK1003 programs at the 2026 ASCO Annual Meeting, showing encouraging response rates and tolerability.
NASDAQ
EIKN
Eikon Therapeutics, INC
8-K: Eikon widens 2025 loss, boosts cash via IPO
Eikon Therapeutics reported a larger 2025 net loss, completed Phase 2 enrollment for EIK1001 in first-line NSCLC, and strengthened liquidity with a $381.2 million upsized IPO, guiding cash runway into 2H 2027.